End-of-day quote
Korea S.E.
06:00:00 2024-07-14 pm EDT
|
5-day change
|
1st Jan Change
|
278,500
KRW
|
+2.20%
|
|
+2.20%
|
+182.74%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
929,693
|
5,046,497
|
3,198,722
|
1,970,174
|
5,137,836
|
14,795,262
|
-
|
-
|
Enterprise Value (EV)
2 |
872
|
5,011
|
2,999
|
1,847
|
5,053
|
14,758
|
14,736
|
14,312
|
P/E ratio
|
-
|
-5,134
x
|
-433
x
|
-241
x
|
-1,515
x
|
2,063
x
|
290
x
|
33.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
31.7
x
|
119
x
|
77.8
x
|
68.4
x
|
53.2
x
|
188
x
|
87.2
x
|
26.8
x
|
EV / Revenue
|
29.7
x
|
118
x
|
72.9
x
|
64.1
x
|
52.4
x
|
187
x
|
86.9
x
|
25.9
x
|
EV / EBITDA
|
-681
x
|
2,540
x
|
-282
x
|
-69.1
x
|
-789
x
|
1,272
x
|
186
x
|
34.2
x
|
EV / FCF
|
899
x
|
-1,456
x
|
-99.3
x
|
-76
x
|
-562
x
|
1,506
x
|
280
x
|
37.7
x
|
FCF Yield
|
0.11%
|
-0.07%
|
-1.01%
|
-1.32%
|
-0.18%
|
0.07%
|
0.36%
|
2.65%
|
Price to Book
|
12.8
x
|
38.5
x
|
23.4
x
|
13.2
x
|
34.2
x
|
95.1
x
|
67.2
x
|
23.9
x
|
Nbr of stocks (in thousands)
|
50,028
|
50,549
|
50,706
|
51,508
|
52,161
|
53,125
|
-
|
-
|
Reference price
3 |
18,583
|
99,833
|
63,083
|
38,250
|
98,500
|
278,500
|
278,500
|
278,500
|
Announcement Date
|
2/12/20
|
3/10/21
|
3/11/22
|
3/13/23
|
3/11/24
|
-
|
-
|
-
|
1KRW in Million2KRW in Billions3KRW Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
29.37
|
42.43
|
41.12
|
28.81
|
96.52
|
78.73
|
169.6
|
552.6
|
EBITDA
1 |
-1.28
|
1.973
|
-10.64
|
-26.72
|
-6.403
|
11.6
|
79.03
|
418.8
|
EBIT
1 |
-2.252
|
0.1037
|
-12.63
|
-29.37
|
-9.737
|
9.6
|
76.8
|
417.5
|
Operating Margin
|
-7.67%
|
0.24%
|
-30.72%
|
-101.97%
|
-10.09%
|
12.19%
|
45.27%
|
75.55%
|
Earnings before Tax (EBT)
1 |
-
|
-2.839
|
-6.885
|
-9.97
|
-3.564
|
8
|
69
|
442.3
|
Net income
1 |
-
|
-0.9696
|
-7.383
|
-8.146
|
-3.372
|
7.2
|
50
|
437.3
|
Net margin
|
-
|
-2.29%
|
-17.95%
|
-28.28%
|
-3.49%
|
9.14%
|
29.48%
|
79.13%
|
EPS
2 |
-
|
-19.44
|
-145.8
|
-159.0
|
-65.00
|
135.0
|
961.3
|
8,249
|
Free Cash Flow
3 |
969.6
|
-3,442
|
-30,198
|
-24,298
|
-8,985
|
9,800
|
52,600
|
379,800
|
FCF margin
|
3,301.93%
|
-8,113.61%
|
-73,432.95%
|
-84,349.5%
|
-9,308.55%
|
12,447.08%
|
31,008.06%
|
68,729.64%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
84,482.76%
|
66,554.2%
|
90,687.68%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
136,111.11%
|
105,200%
|
86,851.13%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/12/20
|
3/10/21
|
3/11/22
|
3/13/23
|
3/11/24
|
-
|
-
|
-
|
1KRW in Billions2KRW3KRW in Million Fiscal Period: December |
2022 Q3
|
2022 Q4
|
---|
Net sales
1 |
-
|
10.52
|
EBITDA
|
-
|
-
|
EBIT
1 |
-
|
-2.756
|
Operating Margin
|
-
|
-26.18%
|
Earnings before Tax (EBT)
1 |
-
|
-3.213
|
Net income
1 |
-6.151
|
-2.188
|
Net margin
|
-
|
-20.79%
|
EPS
|
-143.0
|
-
|
Dividend per Share
|
-
|
-
|
Announcement Date
|
11/11/22
|
3/13/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
57.7
|
35.2
|
199
|
123
|
84.8
|
36.8
|
59.2
|
483
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
2 |
970
|
-3,442
|
-30,198
|
-24,298
|
-8,985
|
9,800
|
52,600
|
379,800
|
ROE (net income / shareholders' equity)
|
-0.96%
|
-3.31%
|
-4.01%
|
-7.22%
|
-2.44%
|
4.7%
|
24.3%
|
110%
|
ROA (Net income/ Total Assets)
|
-0.84%
|
-2.79%
|
-3.51%
|
-3.23%
|
-1.34%
|
3.2%
|
12.5%
|
55.8%
|
Assets
1 |
-
|
34.75
|
210.5
|
251.9
|
250.8
|
225
|
400
|
783.7
|
Book Value Per Share
3 |
1,452
|
2,594
|
2,702
|
2,889
|
2,876
|
2,929
|
4,144
|
11,649
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
8.16
|
5.12
|
13.6
|
6.42
|
1.22
|
1.33
|
-
|
-
|
Capex / Sales
|
27.8%
|
12.07%
|
33.04%
|
22.3%
|
1.26%
|
1.69%
|
-
|
-
|
Announcement Date
|
2/12/20
|
3/10/21
|
3/11/22
|
3/13/23
|
3/11/24
|
-
|
-
|
-
|
1KRW in Billions2KRW in Million3KRW Last Close Price
278,500
KRW Average target price
246,667
KRW Spread / Average Target -11.43% Consensus |
1st Jan change
|
Capi.
|
---|
| +182.74% | 10.53B | | +7.64% | 101B | | +7.76% | 42.63B | | -14.37% | 33.5B | | +82.32% | 29.77B | | -12.27% | 16.14B | | +2.33% | 14.31B | | -8.56% | 11.55B | | +3.67% | 9.2B | | -56.23% | 8.98B |
Biopharmaceuticals
|